Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-53,770
Closed -$15.6M 36
2025
Q1
$15.6M Hold
53,770
0.22% 44
2024
Q4
$14M Hold
53,770
0.21% 47
2024
Q3
$17.3M Hold
53,770
0.25% 37
2024
Q2
$17.9M Sell
53,770
-1,393
-3% -$409K 0.26% 34
2024
Q1
$15.7M Sell
55,163
-888
-2% -$260K 0.23% 36
2023
Q4
$16.1M Sell
56,051
-4,196
-7% -$1.14M 0.27% 35
2023
Q3
$16.2M Sell
60,247
-1,193
-2% -$298K 0.3% 33
2023
Q2
$13.6M Buy
+61,440
New +$14.3M 0.27% 41
2022
Q4
$9.56M Sell
36,400
-1,214
-3% -$325K 0.16% 41
2022
Q3
$8.48M Buy
37,614
+7,884
+27% +$1.91M 0.15% 38
2022
Q2
$7.23M Buy
29,730
+28,296
+1,973% +$6.93M 0.1% 43
2022
Q1
$347K Sell
1,434
-2
-0.1% -$460 0.01% 228
2021
Q4
$326K Buy
+1,436
New +$303K 0.01% 230

Other funds holding AMGN

Alaska Permanent Fund's AMGN Position: Q2 2025 in Review

Alaska Permanent Fund sold out of Amgen (AMGN) in Q2 2025, closing a stake of 53,770 shares — an estimated $15.6M sold.

Alaska Permanent Fund first reported a position in AMGN in Q4 2021 and held it in 13 quarters. The position peaked at $17.9M in Q2 2024. 2,851 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

  • Alaska Permanent Fund reported no remaining Amgen position as of Q2 2025 after selling out during the quarter.
  • Alaska Permanent Fund sold 53,770 Amgen shares in Q2 2025, an estimated $15.6M.
  • Alaska Permanent Fund first reported a position in Amgen in Q4 2021 and held it in 13 quarters.
  • Alaska Permanent Fund's Amgen position peaked at $17.9M in Q2 2024.
  • 2,851 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on Alaska Permanent Fund's 13F filing for Q2 2025, filed 14 Aug 2025.